




RealRate

PHARMACEUTICAL 2022

MEI Pharma Inc.
Rank 247 of 475



RealRate

• Financial Strength Rankings using Artificial Intelligence • www.realrate.ai

The relative strengths and weaknesses of MEI Pharma Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of MEI Pharma Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 91% points. The greatest weakness of MEI Pharma Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 47% points.

The company's Economic Capital Ratio, given in the ranking table, is -104%, being 172% points above the market average of -276%.

| Input Variable | Value in 1000 USD |
|---|-------------------|
| Assets, Current | 164,817 |
| Cost of Goods Sold | 1,408 |
| Intangible Assets | 0 |
| Liabilities, Current | 30,294 |
| Liabilities, Non-Current | 7,370 |
| Other Assets | 7,774 |
| Other Compr. Net Income | 0 |
| Other Expenses | 8.0 |
| Other Liabilities | 95,072 |
| Other Net Income | 19,118 |
| Property and Equipment | 1,507 |
| Research and Development | 69,398 |
| Revenues | 25,535 |
| Selling, General and Administrative Expense | 24,414 |

| Output Variable | Value in 1000 USD |
|--------------------------|-------------------|
| Assets | 174,098 |
| Liabilities | 132,736 |
| Expenses | 95,228 |
| Stockholders Equity | 41,362 |
| Net Income | -50,575 |
| Comprehensive Net Income | -50,575 |
| Economic Capital Ratio | -104% |